Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

Psilocybin could help improve treatment-resistant depression

Staff Writer
Staff Writer 5 years ago
Updated 2019/07/10 at 4:16 AM
Share
SHARE

A recent study is giving new hope for those suffering from difficult-to-treat depression.

According to researchers, psilocybin, a compound found in psychedelic mushrooms, may be useful in treatment-resistant depression. The preliminary study was published in the journal Scientific Reports and has some all ears over its findings.

Researchers began by analyzing functional magnetic resonance imaging (fMRI) data of 19 participants with a diagnosis of treatment-resistant major depression; they did not organize a control group with placebos. Before and after receiving psilocybin, 16 of the 19 participants had their cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) examined by researchers.

In the findings, researchers say all 19 participants exhibited a rapid decrease in depressive symptoms in the first week following treatment with psilocybin. At five weeks in, almost half of all participants, or 47%, continued to show therapeutic conditions.

Psilocybin affected two areas of the brain: the default-mode network and the amygdala, causing participants to feel a ‘reset’ in their brain, according to the study.

“Whole-brain analyses revealed post-treatment decreases in CBF in the temporal cortex, including the amygdala. Decreased amygdala CBF correlated with reduced depressive symptoms,” the study found.

While the results suggest that psilocybin, a serotonin agonist, can have significant benefits on the brain, it shouldn’t be utilized to self-medicate, researchers warned; as its effects on the brain are still poorly understood.

You Might Also Like

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

Study finds no structural brain change during mindfulness-based stress training

Study finds diet may be a contributing factor in ADHD symptoms associated in children

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

ALS experimental drug NU-9 more efficacious than existing FDA-approved drugs

TAGGED: depression, psilocybin, psychedelics
Staff Writer October 18, 2017
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Researchers find link between autism and high socioeconomic status
Next Article Migraines associated with symptoms of depression and anxiety

Recommended

Clinical

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

1 Min Read
Clinical

Study finds no structural brain change during mindfulness-based stress training

1 Min Read
Clinical

Study finds diet may be a contributing factor in ADHD symptoms associated in children

1 Min Read
Clinical

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?